Latvia vs Libya: Access to anti-retroviral drugs, male
Latvia
51.0%
in 2024
Libya
49.0%
in 2023
Latvia rank
116th
Libya rank
119th
Access to anti-retroviral drugs, male over time
- Latvia
- Libya
How they compare
Latvia currently reports 51.0% against 49.0% in Libya, a difference of 2.0%.
The two have swapped places 1 time across 24 shared years of data; in 2000 it was Libya ahead.
Latvia ranks 116th and Libya ranks 119th of 141 countries.
Across the 3 decades both report, Latvia averaged higher in 1 and Libya in 2.
Head to head by decade
| Decade | Latvia | Libya | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.3% | 29.0% | 25.7% | Libya |
| 2010s | 22.3% | 63.9% | 41.6% | Libya |
| 2020s | 48.5% | 47.8% | 0.8% | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Latvia or Libya?
- Latvia, at 51.0% against 49.0% in Libya as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Latvia and Libya?
- 2.0%, with Latvia ahead.
- How many years of comparable data are there for Latvia and Libya?
- 24 years are reported by both, from 2000 to 2023.
- How do Latvia and Libya rank globally for access to anti-retroviral drugs, male?
- Latvia ranks 116th and Libya ranks 119th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.